Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2350
+0.0048 (2.09%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Theriva Biologics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Theriva Biologics stock has a consensus rating of "Buy" and an average price target of $2.50. The average 1-year stock price forecast is 963.83% higher than the current stock price, while the lowest is $1.00 (+325.53%) and the highest is $4.00 (+1,602.13%).
Price Target: $2.50 (+963.83%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Theriva Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Aug '25 | Nov '25 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $1 | Buy | Maintains | $1 | +325.53% | Aug 12, 2026 |
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $4 | Buy | Reiterates | $4 | +1,602.13% | May 6, 2026 |
Financial Forecast
Revenue This Year
300.00K
Revenue Next Year
n/a
from 300.00K
Decreased by -100.00%
EPS This Year
-0.25
from -2.08
EPS Next Year
-0.20
from -0.25
EPS and Forward PE are based on non-GAAP adjusted numbers.